Tempus AI rises after partnering with Daiichi Sankyo for cancer drug
25/03/2026 12:48
** Shares of genetics-testing firm Tempus AI TEM.O rise 2% to $49.34 premarket ** Co says it partnered with Japan's Daiichi Sankyo to use AI to speedily develop a drug for cancer ** Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells ** Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit ** Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug ** Financial terms of the partnership not disclosed ** TEM shares up ~75% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))